Melbourne, Australia, 22 May 2018: Sienna Cancer Diagnostics Ltd, (ASX:SDX) (“Sienna” or “The Company”), a medical technology company developing and commercialising innovative cancer-related tests, is pleased to announce the Company has received its R&D Tax Incentive Refund of $631,691 for the 2017 financial year.
The amount received provides additional non-dilutive capital which will be used to drive the Company’s growth strategies. Sienna expects to receive the refund for the 2018 financial year during the second half of this calendar year.
For further information please download PDF attached:
Download this document
